<DOC>
	<DOCNO>NCT02115386</DOCNO>
	<brief_summary>Primary Objective study evaluate change chronic low grade non-hematological adverse event experience patient treat least 6 month imatinib respond supportive measure , switch nilotinib ( CTCAE grade system ) .</brief_summary>
	<brief_title>Trial Evaluate Improvement Chronic Low-grade AEs Patients With Ph+ CML With Optimal Response Imatinib When Switched Nilotinib</brief_title>
	<detailed_description>Rationale study fact Nilotinib approve treatment chronic phase accelerate phase Philadelphia chromosome positive chronic myelogenous leukemia ( CML ) adult patient resistant intolerant prior therapy include imatinib ( 400 mg BID ) , new diagnosed patient Ph+ CML CP ( 300 mg BID ) . But majority CML patient treat imatinib experience adverse reaction time . The frequently report drug-related adverse reaction edema , nausea vomiting , muscle cramp , musculoskeletal pain , diarrhea rash . Although majority adverse event experience imatinib mild moderate grade either resolve diminish time , low grade adverse event require chronic treatment occur may adversely impact patient 's quality life . This study examine change chronic low grade chronic adverse event , measure CTCAE , patient switch imatinib nilotinib therapy . So , Primary Objective study evaluate change chronic low grade non-hematological adverse event experience patient treat least 6 month imatinib respond supportive measure , switch nilotinib ( CTCAE grade system ) . Primary endpoint : Changes non-hematological AE grade 3 month switch nilotinib . Secondary Objectives : Rate CCyR switch nilotinib ( newly achieve ( absent baseline ) maintain ) month 1 , 3 , 6 , 12 , 18 24 switch nilotinib ; Rate MMR 1 , 3 , 6 , 9 , 12 , 18 24 month switch ; Time duration CCyR MMR switch study end ; Time first document optimal improvement non-hematological adverse event ( ) associate imatinib ; Overall nilotinib safety profile ; QOL change switch nilotinib within study period - measure baseline ( imatinib ) 1 , 3 , 6 , 12 , 24 month ; Evaluation patient ' experience switch imatinib nilotinib due low-grade chronic toxicity ( diary ) Study Design : Open-label , single arm study assess change chronic low grade adverse event CML-CP patient switch imatinib nilotinib therapy . Patients must treat start imatinib dose 400 mg least 300mg QD imatinib ≥ 6 month experience ≤ Grade 2 adverse event persist ≥ 2 month despite maximal supportive care . Patients optimal responder imatinib accord LeukemiaNet 2009 criterion study entrance . Adverse event grade accord CTCAE guideline baseline assess throughout trial visit . Patients treat nilotinib 300mg BID study follow 2 year . Number patient &amp; center : 40 patient , 8 center .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Male female patient ≥ 18 year age ECOG ≤ 2 Diagnosis CMLCP &lt; 15 % blast peripheral blood bone marrow &lt; 30 % blast plus promyelocytes peripheral blood bone marrow &lt; 20 % basophils peripheral blood ≥ 100 x 109 /L platelet No evidence extramedullary leukemic involvement , exception hepatosplenomegaly . Optimal response imatinib accord LeukamiaNet 2009 criterion define : MCR 6 month start imatinib CCR 12 month start imatinib MMR 18 month start imatinib ( MMR response define either 3 log reduction bcrabl/abl ratio 0,1 % IS ) . Initial treatment 400mg imatinib current treatment imatinib 400 mg 300 QD . Imatinib dose interruption allow prior inclusion exceed 28 consecutive day Persistent Grade 1 2 nonhematological adverse event least 2 month despite supportive care . Toxicity evaluate treat physician use CTCAE criterion . In case several type nonhematological AEs Adequate end organ function define Total bilirubin &lt; 1.5 x ULN SGOT ( AST ) SGPT ( ALT ) &lt; 2.5 x ULN Creatinine &lt; 1.5 x ULN Serum amylase lipase ≤ 1.5x ULN Alkaline phosphatase ≤ 2.5 x ULN unless consider tumor related Serum potassium magnesium value ≥ LLN ( low limit normal ) correct within normal limit supplement prior first dose study medication . Patients must imatinib washout period least 3 day exceed 7 day prior first dose nilotinib . Ability provide write informed consent prior study related screening procedure do minimal duration imatinib therapy 6 month Loss response ( hematologic , cytogenetic , molecular ) time prior inclusion Prior accelerate phase blast phase CML Previously document T315I mutation Presence chromosomal abnormality ( trisomy 8 ) and/or clonal evolution Ph+ . Any grade &gt; 2 nonhematological AEs inclusion within 30 day prior inclusion . Previous treatment imatinib &gt; 400 mg anytime prior inclusion . Previous treatment tyrosine kinase inhibitor except imatinib . Impaired cardiac function include follow : LVEF &lt; 45 % determine echocardiogram reading MUGA Complete leave bundle branch block Use ventricularpaced pacemaker Congenital long QT syndrome know family history long QT syndrome History presence clinically significant ventricular atrial tachyarrhythmias Clinically significant rest bradycardia ( &lt; 50 beat per minute ) QTcF &gt; 450 msec baseline ECG . If QTcF &gt; 450 electrolyte within normal range , electrolyte correct patient rescreened QTcF Myocardial infarction within 1 year start study drug Other clinically significant heart disease ( e.g. , unstable angina , congestive heart failure , uncontrolled hypertension ) Right bundle branch block plus leave anterior hemiblock , bifascicular block Patients receive therapy inhibitor CYP3A4 medication prolong QT interval either discontinue switched different medication prior start study drug . Treatment strong CYP3A4 inducer ( e.g . phenytoin , carbamazepine , rifampin , rifabutin , rifapentine , phenobarbital , St. John 's Wort ) , treatment discontinue switched different medication prior start study drug . Impaired gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug . History acute pancreatitis within 1 year study entry document past medical history chronic pancreatitis . Known cytopathologically confirm CNS infiltration ( absence suspicion CNS involvement , lumbar puncture require ) . Any malignancy clinically significant require active intervention . Severe uncontrolled medical condition ( i.e. , uncontrolled diabetes , active uncontrolled infection ) . Acute chronic liver severe renal disease consider unrelated disease . History significant congenital acquire bleed disorder unrelated cancer . Previous radiotherapy ≥ 25 % bone marrow . Major surgery within 4 week prior Day 1 study recover prior surgery . Treatment investigational agent within 30 day Day 1 . History noncompliance medical regimen inability grant consent . Women pregnant , breast feeding , childbearing potential without negative serum test baseline . Male female patient childbearing potential unwilling use contraceptive precaution throughout trial 3 month follow discontinuation study drug . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Women childbearing potential must negative serum pregnancy test within 7 day first dose nilotinib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Ph+ CML , chronic myeloid leukemia</keyword>
</DOC>